3 years 0.92
Extreme 0.92
22.5
5 years 0.92
Extreme 0.92
65.08
10 years 0.92
Extreme 0.92
133
Manager TitleAgeSince
Chief Executive Officer - 14/08/2025
Chief Tech/Sci/R&D Officer - 01/01/2019
Chief Tech/Sci/R&D Officer - 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/25 Issuer sale

Director

54,235 0.1592%
14/08/25
Topsøe Holding A/S
Issuer saleCompany 50,44,295 16.5208%
14/08/25 Issuer sale

Chief Executive Officer

3,23,680 0.9498%
Change 5-day change 1-year change 3-year change Capi.($)
-2.31%-.--% - - 7.66Cr
+0.88%-0.34%+40.64%+73.05% 6.47TCr
-0.26%+6.91%+11.14%+77.36% 5.48TCr
+0.47%+3.52%+8.22%+100.95% 5.35TCr
-2.06%+2.90%+24.07%+48.36% 4.6TCr
-1.79%+0.19%+19.32%+123.62% 4.29TCr
-1.65%+0.96%+237.56%+823.66% 4.01TCr
-2.26%-4.14%+15.38%+45.53% 3.35TCr
-2.96%-11.01%+19.47%-6.72% 2.4TCr
+12.10%+16.60%+55.14%+46.15% 2.37TCr
Average +0.02%+1.27%+47.88%+147.99% 4.26TCr
Weighted average by Cap. -0.08%+1.62%+45.48%+149.73%
Logo IGM Biosciences, Inc.
IGM Biosciences LLC, formerly known asIGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins.
Employees
16
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - IGM Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. IGMS Stock